Zhang, X., Jiang, J., Xu, J., Chen, J., Gu, Y., & Wu, G
This context supports conversations with providers about whether slower tapering, bridge therapies, or lifestyle intensification would be prudent
1 Department of Clinical and Biomedical Sciences, Exeter, UK, 2 University of Geneva, Geneva, Switzerland, 3 Level 3, Exeter University, Exeter, UK, 4 Benaroya Research Institute, Seattle, WA, USA, 5 University of Melbourne, Parkville, Australia, 6 The Hospital for Sick Children, Toronto, ON, Canada, 7 Yale University School of Medicine, New Haven, CT, USA, 8 Texas Childrens Hospital, Houston, TX, USA, 9 Indiana Diabetes Research Center, Indiana University, Indianapolis, IN, USA, 10 Miller School of Medicine, Miami, FL, USA, 11 Indiana University School of Medicine, Indianapolis, USA, 12 Institute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, UK
Understanding GLP-1 dosing in midlife requires looking at the full metabolic picture
2.	Ali M